A Phase I - II Study of the Safety and Efficacy of a True Human Antibody
Staphylococcal bacteremia is a serious infection that despite intravenous antibiotic therapy still has a mortality of 20 to 40%. Previous attemopts to augment antibiotic therapy with passive immunization strategies have been met with limited success, due to the presence of the virulence factor, Staphylococcal Protein A (SpA). SpA binds the Fc region of immunoglobulins, effectively neutralizing them, which interferes with complement activation and phagocytosis.
Who may be Eligible
Patients =18 years of age who have Bacteremia Due to Staphylococcus Aureus